OncLive TV

Rebecca L. Porter, MD, PhD, discusses the evaluation of mirvetuximab soravtansine plus pembrolizumab in FRα-positive, pMMR/MSS endometrial cancer.

Debra L. Richardson, MD, FACS, FACOG, discusses outcomes seen with upifitamab rilsodotin in the phase 1/2 UPLIFT trial for patients with ovarian cancer.

Deborah J. Wong, MD, PhD, discusses the evaluation of atezolizumab vs placebo after definitive local therapy in high-risk, locally advanced HNSCC.

Michael R. Migden, MD, discusses efficacy data for RP1 in advanced non-melanoma skin cancer after prior solid organ transplant.

Saad Z. Usmani, MD, MBA, FACP, FASCO, discusses the FDA approval of cilta-cel for relapsed/refractory multiple myeloma.

Samilia Obeng-Gyasi, MD, MPH, discusses breast cancer mortality rates in resource-poor neighborhoods.

Saad J. Kenderian, MB, CHB, consultant, discusses the safety and efficacy findings derived from the phase 1/2 TRANSCEND CLL 004 study in CLL/SLL.

Neel P. Chudgar, MD, discusses his presentation on resectability in non–small cell lung cancer at the 21st Annual Winter Lung Cancer Conference®.

Wenxin (Vincent) Xu, MD, discusses ongoing efforts to identify new biomarkers in metastatic renal cell carcinoma.

Danai Dima, MD, discusses real-world responses with teclistamab in relapsed/refractory multiple myeloma.

Jaime Schneider, MD, PhD, discusses considerations for patients with EGFR-mutant non–small cell lung cancer that progresses on osimertinib.

Rebecca Kristeleit, BSc, MBChB, MRCP, PhD, on efficacy outcomes from the 3-year follow-up for patients with advanced ovarian cancer in the ATHENA-MONO study.

Manish A. Shah, MD, discusses 5-year outcomes from the KEYNOTE-590 trial of frontline pembrolizumab plus chemotherapy in patients with esophageal cancer.

Catherine C. Coombs, MD, discusses the mechanism of action of noncovalent BTK inhibitors in patients with relapsed/refractory mantle cell lymphoma.

Krina K. Patel, MD, MSc, discusses the FDA approval of ide-cel for patients with triple class–exposed relapsed/refractory multiple myeloma.

Petros Grivas, MD, PhD, discusses potential future directions for adjuvant therapies in patients with resected renal cell carcinoma.

Ariel Grajales-Cruz, MD, discusses the rationale for a real-world study of teclistamab in patients with myeloma who had received BCMA-directed therapy.

Daniel Petrylak, MD, discusses emerging therapeutic targets showing early potential in metastatic urothelial cancer.

Samuel Kareff, MD, MPH, discusses the treatment of patients with non–small cell lung cancer.

Rita Nanda, MD, discusses the future of neoadjuvant treatment for patients with HER2-positive breast cancer.

Andrew Ip, MD, discusses the implications of using next-generation sequencing alongside machine learning in the diagnosis of hematologic malignancies.

Daniel Petrylak, MD, discusses treatment with enfortumab vedotin plus pembrolizumab in patients with urothelial carcinoma in the community setting.

Ajay K. Nooka, MD, MPH, FACP, discusses the CLOVER-WaM trial of iopofosine I 131 for heavily pretreated, refractory Waldenström macroglobulinemia.

Carlos Arteaga, MD, discusses the resistance to CDK4/6 inhibitors in estrogen receptor–positive breast cancer.

Sagar Patel, MD, discusses the utility of the Orca-T platform in patients with hematologic malignancies, highlighting the platform's safety.

Ticiana Leal, MD, discusses the investigation of patritumab deruxtecan in the HERTHENA-Lung01 study in advanced EGFR-mutated non–small cell lung cancer.

Gautam Jha, MD, discusses collaborative efforts between community and academic oncologists to accrue patients to the ECLIPSE trial.

Ben Creelan, MD, discusses survival outcomes with cemiplimab in patients with squamous non–small cell lung cancer.

Emmanuel Antonarakis, MD, and Gautam Jha, MD, on collaboration efforts extending the reach of clinical trials beyond university hospitals.

Sebastian Stintzing, MD, discusses the Q-TWiST analysis of fruquintinib plus best supportive care in metastatic colorectal cancer.